Allergan Adds Device To Glaucoma Portfolio
This article was originally published in The Gray Sheet
The pharmaceutical firm is entering the highly touted micro-invasive glaucoma surgery space with an acquisition of AqueSys, adding a device to its established portfolio of glaucoma drugs.
You may also be interested in...
FDA issued a "leap frog" draft guidance for minimally invasive glaucoma surgery (MIGS) devices based on strong interest in the nascent field from manufacturers. The recommendations under the guidance reflect discussion during a 2014 stakeholder workshop.
Two Massachusetts-based infusion pump manufacturers with the same founder and CEO received warning letters from the US FDA for similar violations.
More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.